Assessment of Macrophage Activation syndromE in STill's Disease in Italy (AMETISTA)

Sobi

Status: Completed

Conditions: Still's Disease, Adult-Onset; Still Disease, Juvenile Onset; Macrophage Activation Syndrome (MAS)

Study type: Observational

Funder types: Industry

Identifiers

NCT06992505

Sobi.EMAPALUMAB-106

Details and patient eligibility

About

Assessment of macrophage activation syndrome in Still's disease:

retrospective chart analysis of patient history, symptom resolution and treatment characteristics in Italy

Full description

This is an observational, retrospective cohort study on the treatment utilization and outcomes of Macrophage Activation Syndrome (MAS) refractory to glucocorticoids (GC) in patients with Still's disease. The study will be conducted entirely through medical chart abstraction; all data will be taken from the patient's medical record, with no additional assessments. The study will be conducted in Italy.

Enrollment: 32 patients

Sex: All

Ages: 6 months to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age >6 months and ≤80 years at the beginning of the index MAS episode.
• Diagnosis of Still's disease (sJIA or AOSD diagnosis).
• Diagnosis of MAS according to treating physician in the medical record.
• Patients who have received at least 3 consecutive days of GC after diagnosis of MAS and/or are judged by the Investigator to be refractory to GC due to clinical worsening of patient's condition.
• The onset of the index MAS episode occurred between 01 January 2012 and 30 September 2022.
• According to local regulations, waivers of consent will be sought for study participants from the appropriate regulatory authorities and/or the independent ethics committee (IEC)/institutional review board (IRB). o For patients not covered by waivers of consent, signed, and dated informed consent provided by the patient, or the patient's legally authorized representative(s) for patients under the legal age (with patient assent, as applicable) or who have died, should be obtained before any study-related activities are undertaken.

Exclusion criteria

• A diagnosis of primary HLH prior to the beginning of the index MAS episode.
• Confirmed malignancy prior to the beginning of the index MAS episode.
• Patient treated with any investigational product as a part of clinical trial during the index MAS episode.